Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children
- PMID: 21102987
- PMCID: PMC2954695
- DOI: 10.1093/sleep/33.11.1457
Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children
Abstract
Study objective: to report on symptoms and therapies used in childhood narcolepsy-cataplexy.
Design, patients, and setting: retrospective series of 51 children who completed the Stanford Sleep Inventory. HLA-DQB1*0602 typing (all tested, and 100% positive), polysomnography or Multiple Sleep Latency Test (76%), and cerebrospinal fluid hypocretin-1 measurements (26%, all with low levels) were also conducted. Prospective data on medication response was collected in 78% using a specially designed questionnaire.
Measurements and results: patients were separated into children with onset of narcolepsy prior to (53%), around (29%), and after (18%) puberty. None of the children had secondary narcolepsy. Clinical features were similar across puberty groups, except for sleep paralysis, which increased in frequency with age. Common features included excessive weight gain (84% ≥ 4 kg within 6 months of onset of narcolepsy) and earlier puberty (when compared with family members), notably in subjects who gained the most weight. Streptococcus-positive throat infections were reported in 20% of cases within 6 months of onset of narcolepsy. Polysomnographic features were similar across groups, but 3 prepubertal children did not meet Multiple Sleep Latency Test diagnostic criteria. Regarding treatment, the most used and continued medications were modafinil (84% continued), sodium oxybate (79%), and venlafaxine (68%). Drugs such as methylphenidate, tricyclic antidepressants, or selective serotonin reuptake inhibitors were often tried but rarely continued. Modafinil was reported to be effective for treating sleepiness, venlafaxine for cataplexy, and sodium oxybate for all symptoms, across all puberty groups. At the conclusion of the study, half of children with prepubertal onset of narcolepsy were treated "off label" with sodium oxybate alone or with the addition of one other compound. In older children, however, most patients needed more than 2 drugs.
Conclusion: this study reports on the clinical features of childhood narcolepsy and documents the safe use of treatments commonly used in adults in young children.
Keywords: DQB1*0602; HLA; MSLT; Narcolepsy; cataplexy; childhood; hypocretin; modafinil; orexin; sodium oxybate; venlafaxine.
Similar articles
-
Sodium oxybate improves excessive daytime sleepiness in narcolepsy.Sleep. 2006 Jul;29(7):939-46. doi: 10.1093/sleep/29.7.939. Sleep. 2006. PMID: 16895262 Clinical Trial.
-
Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.Sleep Med. 2016 Aug;24:57-62. doi: 10.1016/j.sleep.2016.07.010. Epub 2016 Aug 22. Sleep Med. 2016. PMID: 27810187 Clinical Trial.
-
EFNS guidelines on management of narcolepsy.Eur J Neurol. 2006 Oct;13(10):1035-48. doi: 10.1111/j.1468-1331.2006.01473.x. Eur J Neurol. 2006. PMID: 16987156
-
Treatment of narcolepsy and other hypersomnias of central origin.Sleep. 2007 Dec;30(12):1712-27. doi: 10.1093/sleep/30.12.1712. Sleep. 2007. PMID: 18246981 Free PMC article. Review.
-
[Diagnostic and therapeutic update in narcolepsy].Rev Neurol. 2012 May 21;54 Suppl 3:S25-30. Rev Neurol. 2012. PMID: 22605629 Review. Spanish.
Cited by
-
Narcolepsy: neural mechanisms of sleepiness and cataplexy.J Neurosci. 2012 Sep 5;32(36):12305-11. doi: 10.1523/JNEUROSCI.2630-12.2012. J Neurosci. 2012. PMID: 22956821 Free PMC article. Review. No abstract available.
-
Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.J Clin Sleep Med. 2022 Sep 1;18(9):2217-2227. doi: 10.5664/jcsm.10090. J Clin Sleep Med. 2022. PMID: 35689598 Free PMC article. Clinical Trial.
-
Clinical and polysomnographic course of childhood narcolepsy with cataplexy.Brain. 2013 Dec;136(Pt 12):3787-95. doi: 10.1093/brain/awt277. Epub 2013 Oct 18. Brain. 2013. PMID: 24142146 Free PMC article.
-
Presentations of primary hypersomnia in Chinese children.Sleep. 2011 May 1;34(5):627-32. doi: 10.1093/sleep/34.5.627. Sleep. 2011. PMID: 21532956 Free PMC article.
-
Narcolepsy following COVID-19: A case report and review of potential mechanisms.Clin Case Rep. 2023 May 25;11(6):e7370. doi: 10.1002/ccr3.7370. eCollection 2023 Jun. Clin Case Rep. 2023. PMID: 37251741 Free PMC article.
References
-
- Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6:991–7. - PubMed
-
- Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437–51. - PubMed
-
- Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365–76. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials